UNSPSC 51351604: Altrenogest

This classification denotes a progestagen with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U0X0JA2NB, chemically known as 17-alpha-allyl-estratriene-4,9,11,17-beta-ol-3-one but generally known as altrenogest, which bears US NIH Compound Identifier 13324. European Medicines Agency schedules Altrenogest in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05381MIG. The term ALTRENOGEST is an International Non-Proprietary Name.

UNSPSC 51351604 Altrenogest (Commodity) covers veterinary pharmaceutical products, but the recent state and local procurement activity tagged under this code reflects a broader multistate cooperative purchasing initiative for generic pharmaceuticals and over-the-counter products distributed across state and local government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body pursuing contracts under this code. State procurement offices and health or human services agencies in participating jurisdictions—including Oregon—are the end users. Vendors responding to opportunities here supply pharmaceutical manufacturers and wholesalers providing products through authorized distribution channels (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC). The scope includes comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, detailed product information submissions (NDC codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging and manufacturing locations), and contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain commercial general liability coverage of $5,000,000 per occurrence and professional liability of $2,000,000, and ensure all products meet FDA requirements with expiration dates of at least one year from manufacture and a minimum six-month shelf life.

MMCAP's most recent opportunity for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026) operates across Minnesota and participating states including Oregon. Proposals closed in March 2026; awarded vendors will be provided to authorized wholesalers by May 15, 2026, with contract effectiveness on July 1, 2026. The two-year contract term includes optional extensions at MMCAP's sole discretion, and evaluation is weighted heavily toward price competitiveness (75 percent), with lesser weight on fixed pricing (10 percent), compliance with administrative format requirements (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). No set-aside designations or restrictions for disadvantaged enterprises appear in the available documentation. Vendors must submit through the ePro procurement system using Google Chrome, with pricing and product information provided in designated Excel spreadsheet format converted to CSV. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.